<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263977</url>
  </required_header>
  <id_info>
    <org_study_id>THEMIS</org_study_id>
    <nct_id>NCT01263977</nct_id>
  </id_info>
  <brief_title>Thermodilution - Controlled Management of Volume Therapy in Septic Shock</brief_title>
  <acronym>THEMIS</acronym>
  <official_title>A Randomized Mono-center Study Looking at the Effect of Thermodilution Controlled Therapy for Volume Optimization on the Duration of Septic Shock in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Claudia Spies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock and multi-organ failure are among the most frequent causes of death in the ICU.

      Patients with septic shock require early implementation of hemodynamic therapy to keep the
      duration of shock state and with it microcirculatory disturbances as short as possible. In
      the septic shock guidelines by the american association SCCM the diagnosis of volume status
      is based on filling pressures, like CVP. Some studies show, that the CVP depends not only on
      the intravascular volume, but also on the right ventricular compliance, pulmonary vascular
      resistance as well as intrathoracic pressure. The aim of the Study is to evaluate if the
      duration of septic shock can be reduced through algorithm driven volume therapy orientated to
      thermodilution based volume parameters (GEDI and ELWI)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of septic shock</measure>
    <time_frame>6 months</time_frame>
    <description>septic shock is defined as sepsis with mean arterial pressure (MAP) &lt;65mmHg or systolic arterial pressure (SAP) &lt;90mmHg or the need for vasopressors to support the MAP &gt;/= 65 mmHg or the SAP &gt;/= 90 mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>max 28 Tage</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90 and 180 days mortality</measure>
    <time_frame>max 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care mortality</measure>
    <time_frame>max 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of arterial hypoperfusion in the extremity of the thermodilution</measure>
    <time_frame>max. 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Septic Shock</condition>
  <condition>Volume Status</condition>
  <arm_group>
    <arm_group_label>Thermodilution controlled volume management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volume management based on parameters: GEDI, ELWI, CI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volume management based on surviving sepsis campaign</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>volume management based on surviving sepsis campaign guidelines: CVP, Urin output, MAP, ScvO2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Picco- thermodilution catheter</intervention_name>
    <description>Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral</description>
    <arm_group_label>Thermodilution controlled volume management</arm_group_label>
    <arm_group_label>Volume management based on surviving sepsis campaign</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent from patient, authorized proxy, carer

          -  In women of child bearing age, effective contraceptive use with a known failure rate
             of &lt;1 %

          -  Clinical verification of infection (≥ 48 hours possible), with at least one criteria
             from a - d required:

               1. Proof of pathological microorganism in blood, sputum, urine or normally sterile
                  body tissues

               2. Identifiable focus (e.g. purulent sputum or wound secretion, perforated gut)

               3. Identification of granulocytes in normally sterile tissue

               4. Clinical suspicion of infection without identification of pathogens or
                  micro-organisms (e.g. new pulmonary infiltrates on chest x-ray, treated
                  pneumonia, purpura fulminants, necrotizing fasciitis)

          -  Confirmation of SIRS (≥ 48 hours possible), with at least 2 criteria from a-d
             required:

               1. Fever (≥38 °C) or Hypothermia (≤ 36 °C)

               2. Tachycardia (≥ 90/min)

               3. Tachypnoea (≥ 20/min) or Hyperventilation (PaCO2 ≤ 32 mmHg, ≤ 4,4 kPa) or
                  mechanical ventilation

               4. Leukocytes (≥ 12,000/μl) or Leucopenia (≤ 4,000/μl) or ≥ 10% immature
                  granulocytes

          -  Sepsis-induced HYPOTENSION despite adequate volume status (&lt;24h):

        Mean arterial pressure (MAP) &lt; 65 mmHg (&lt; 8,7 kPa) or systolic arterial pressure (SAP) &lt; 90
        mmHg (&lt; 12 kPa) or the need for vasopressor (Norepinephrine &lt;0.05µg/kg/min) to support the
        MAP ≥ 65 mmHg (≥ 8,7 kPa) or the SAP ≥ 90 mmHg ≥ 12 kPa), when one of these criteria has
        lasted for 4 hours or longer.

        Exclusion Criteria:

          -  Therapy limited (DNR-Order)

          -  Patient moribund

          -  Pregnancy (positive pregnancy test in women of child bearing age)

          -  Breast feeding women

          -  Age &lt; 18 years

          -  Patients active treatment for congestive heart failure with Ejection fraction &lt; 30%
             and/or NYHA Class IV congestive heart failure

          -  Severe peripheral Arterial Vascular Occlusion Disease ≥ 2b after Fontaine

          -  Patients with Glasgow Coma Score ≤ 8 at the time of admission and prior to the
             administration of medications such as sedatives

          -  Patients with TNM stage 4 solid tumors, hematologic malignancies with high tumor
             burden, CNS tumors (WHO stage 4)

          -  Patients who are likely to die within days for diseases or conditions other than
             catecholamine-dependent shock

          -  Participation in another interventional clinical study within the last 30 days

          -  Particular relationship to senior investigator (e.g. staff, relative, colleague)

          -  Patients with severe liver dysfunction (Child C)

          -  Patients with septic shock within the last 60 days

          -  Patients receiving norepinephrine for longer than 48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia D Spies, MD, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Anesthesiology and Intensive Care Medicine, CCM and CVK, Charité - Universitaetsmedizin Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Sander, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Anesthesiology and Intensive Care Medicine, CCM and CVK, Charité - Universitaetsmedizin Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology and Intensive Care Medicine Campus Charité Mitte and Campus Virchow-Klinikum, Charité - Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin,</city>
        <state>Berlin</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Claudia Spies</investigator_full_name>
    <investigator_title>Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Charite University, Berlin, Germany</investigator_title>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>goal directed volume therapy</keyword>
  <keyword>outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

